ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 865,97
0,36%
Dow Jones
44 156,73
0,00%
DAX
21 312,18
0,25%
Brent Oil
78,615
0,36%
Bitcoin
101 509,67
-2,05%
Registration Strip Icon for charts Inscrivez-vous pour des graphiques en temps réel, des outils d'analyse et des prix.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Royaume-Uni
  5. LSE
  6. Biogen Inc (0R1B)

  7. Biogen Inc (0R1B) Actualités

0R1B

Biogen (0R1B)

Biogen Inc
De:
Trier par:
 Showing the most relevant articles for your search:LSE:0R1B
DateHeureSourceTitreSymboleSociété
23/01/202513h30UK RegulatoryFDA and EMA Accept Applications for Higher Dose Regimen of Nusinersen in SMALSE:0R1BBiogen Inc
14/01/202501h05UK RegulatoryFDA Accepts LEQEMBI® (lecanemab-irmb) Biologics License Application for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer’s DiseaseLSE:0R1BBiogen Inc
19/11/202407h00UK RegulatoryDapirolizumab Pegol Phase 3 Data Presented at the American College of Rheumatology Shows Significant Reduction in Systemic Lupus Erythematosus Disease ActivityLSE:0R1BBiogen Inc
14/11/202417h23UK RegulatoryEisai Receives Positive Opinion from the CHMP in the European Union for Lecanemab in Early Alzheimer’s DiseaseLSE:0R1BBiogen Inc
31/10/202400h30UK RegulatoryEisai Presents Data on Benefits of Long-Term Administration of Dual-Acting Lecanemab at the 17th Clinical Trials for Alzheimer’s Disease (CTAD) ConferenceLSE:0R1BBiogen Inc
29/10/202423h00UK RegulatoryBiogen and Neomorph Announce Multi-Target Research Collaboration to Discover and Develop Molecular Glue Degraders for Alzheimer’s, Rare, and Immunological DiseasesLSE:0R1BBiogen Inc
29/10/202413h00UK RegulatoryBiogen Appoints Daniel Quirk, MD, as Chief Medical OfficerLSE:0R1BBiogen Inc
28/10/202413h30UK RegulatoryMichael McDonnell, Executive Vice President and Chief Financial Officer to Retire in February 2025LSE:0R1BBiogen Inc
27/10/202402h15UK RegulatoryBiogen Presents Positive Results from Phase 2 IGNAZ Study of Felzartamab in IgA Nephropathy at American Society of Nephrology (ASN) Kidney Week 2024LSE:0R1BBiogen Inc
24/10/202413h30UK RegulatoryBiogen to Present New Data at the Clinical Trials on Alzheimer's Disease (CTAD) 2024 Annual ConferenceLSE:0R1BBiogen Inc
22/10/202413h30UK RegulatoryBiogen Announces Late Breaker and New Data Presentations at American Society of Nephrology (ASN) Kidney Week 2024LSE:0R1BBiogen Inc
09/10/202413h30UK RegulatoryBiogen Receives U.S. FDA Breakthrough Therapy Designation for Felzartamab for the Treatment of Antibody-Mediated Rejection in Kidney Transplant RecipientsLSE:0R1BBiogen Inc
08/10/202413h30UK RegulatoryNew Higher Dose Nusinersen Efficacy and Safety Data Presented at World Muscle Society Congress, Highlight Potential to Maximize Benefit of Nusinersen in SMALSE:0R1BBiogen Inc
24/09/202407h00UK RegulatoryUCB and Biogen Announce Positive Topline Results From Phase 3 Study of Dapirolizumab Pegol in Systemic Lupus Erythematosus and are Initiating Second Phase 3 Study in 2024LSE:0R1BBiogen Inc
12/09/202413h30UK RegulatoryBiogen Board Appoints Two New Independent DirectorsLSE:0R1BBiogen Inc
04/09/202413h30UK RegulatoryBiogen Announces Positive Topline Results from Study of Higher Dose Regimen of Nusinersen, Showing Significant Benefit in Treatment of SMALSE:0R1BBiogen Inc
30/07/202423h15UK RegulatoryNew Clinical Data Demonstrates Three Years of Continuous Treatment with Dual-Acting LEQEMBI® (lecanemab-irmb) Continues to Significantly Benefit Early Alzheimer’s Disease Patients Presented at The Alzheimer’s Association International Conference (AAICLSE:0R1BBiogen Inc
30/07/202413h30UK RegulatoryBiogen, Beckman Coulter and Fujirebio to Collaborate on Blood-Based Biomarkers and Test for Tau Pathology in Alzheimer’s DiseaseLSE:0R1BBiogen Inc
26/07/202413h20UK RegulatoryUpdate on Regulatory Review of Lecanemab for Early Alzheimer’s Disease in the European UnionLSE:0R1BBiogen Inc
06/03/202413h30UK RegulatoryNew Biomarker Data Add Further Evidence Supporting the Potential Benefit of SPINRAZA® (nusinersen) in Infants and Toddlers with Unmet Clinical Needs after Gene TherapyLSE:0R1BBiogen Inc
04/03/202422h15UK RegulatoryBiogen Highlights New Data at the International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PD™) 2024 Annual MeetingLSE:0R1BBiogen Inc
23/02/202413h00UK RegulatoryBiogen’s QALSODY® (tofersen), the First Therapy to Treat Rare, Genetic Form of ALS, Received Positive Opinion from CHMPLSE:0R1BBiogen Inc
12/02/202422h06UK RegulatoryBiogen Received European Commission Approval for SKYCLARYS® (omaveloxolone), the First Therapy to Treat Friedreich’s AtaxiaLSE:0R1BBiogen Inc
31/01/202413h30UK RegulatoryBiogen to Realign Resources for Alzheimer's Disease FranchiseLSE:0R1BBiogen Inc
06/08/202318h07Alliance NewsAlliance NewsCORRECT: Biogens, Sage Therapeutics postpartum depression drug okayedLSE:0R1BBiogen Inc
06/08/202315h17Alliance NewsAlliance NewsBiogens, Sage Therapeutics postpartum depression treatment approvedLSE:0R1BBiogen Inc
09/06/202313h12Alliance NewsAlliance News*Nasdaq halts trading of Biogen stockLSE:0R1BBiogen Inc
13/01/202015h28Alliance NewsAlliance NewsPfizer Could Net USD635 Million As Biogen Acquires Alzheimer's DrugLSE:0R1BBiogen Inc
 Showing the most relevant articles for your search:LSE:0R1B

Dernières Valeurs Consultées

LSE
0E4H
BNP Paribas Easy MSCI Ja...
KUCN
UBXUSDT
UBIX.Network
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2025 ADVFN PLC - Tous droits réservés